// App-Quantinova.ai

12108 : Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.

Researchers

Presenter

  • Yan Zhang

Principal Investigators

  • Jun Zhao

  • Renhua Guo

  • Gen Lin

  • Li Liu

  • Chenchen Zhu

  • Naixin Liang

  • Huaxia Yang

  • Wen xian Wang

  • Pingping Dai

  • Yan-Fang Guan

  • Ling Yang

  • Xin Yi

  • Xuefeng Xia

Medical Centers

  • Geneplus-Beijing Institute, Changping District, Beijing, China

  • Beijing University School of Oncology Beijing Institute for Cancer Research, Beijing, China

  • Second Affiliated Hospital of Dalian Medical University, Dalian, China

  • Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Zhejiang Cancer Hospital, Hangzhou, China

  • Geneplus-Beijing Institute, Beijing, China

  • Houston Methodist Research Institute, Weill Cornell School of Medicine, Houston, TX

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Tagrisso

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final